Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.50 USD
-0.12 (-4.57%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.49 -0.01 (-0.40%) 6:14 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.50 USD
-0.12 (-4.57%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.49 -0.01 (-0.40%) 6:14 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
by Zacks Equity Research
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
by Zacks Equity Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?
by Zacks Equity Research
Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
by Zacks Equity Research
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
by Zacks Equity Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs
by Zacks Equity Research
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
by Zacks Equity Research
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA
by Zacks Equity Research
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.
Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3
by Zacks Equity Research
Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.
Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter loss is wider than expected. The company is progressing well in terms of development of its pipeline candidates.
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag
by Zacks Equity Research
Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.
Cellectis (CLLS) Jumps: Stock Rises 9%
by Zacks Equity Research
Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
by Zacks Equity Research
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLLS) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Cellectis
by Zacks Equity Research
Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLLS) Outperforming Other Medical Stocks This Year?
Cellectis' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cellectis.
How Cellectis (CLLS) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 12th.
What Makes Cellectis S.A. (CLLS) a New Strong Buy Stock
by Zacks Equity Research
Cellectis S.A. (CLLS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.